« Return to News | R&D Trends

Spaulding Clinical Research partners with Clinigene

Tuesday, August 23, 2011 11:04 AM

Spaulding Clinical Research has partnered with Clinigene International, part of the Biocon, based in Bangalore, India, to broaden and globalize its research services offering, according to PharmaTimes.

The strategic partnership with Clinigene International establishes a “reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services,” giving both companies an opportunity to “engage pharmaceutical clients strategically and accelerate first-in-human to proof-of-concept clinical development,” Spaulding said.

While Clinigene can offer preclinical development services through its sister-company Syngene, Spaulding will cover the FIH/SAD/MAD (first in human/ single ascending dose/multiple ascending dose) end.

Clinigene also provides DDI (drug-drug interaction) and proof-of-concept services, backed up by its central and bioanalytical laboratories.

“With Clinigene’s expertise and cost-effective approach to BA/BE [bioavailability.bioequivalence] and Spaulding’s market-leading TQT [cardiac risk] study and Cardiac Core Lab expertise, our clients are able to easily structure a program for their compound that delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound,” said  Randol Spaulding, chief executive officer of Spaulding Clinical.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.